- RBT-1 is actively enrolling in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery- SOUTHLAKE, Texas, Oct. 3, 2024 ...
RBT-1 achieved the primary biomarker endpoint, as well as several key clinical outcome endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results